新辅助化疗与初始减瘤手术在晚期输卵管卵巢癌中的比较:EORTC 55971与CHORUS试验个体患者数据的汇总分析
该汇总分析纳入EORTC 55971和CHORUS两项随机试验的1220例晚期输卵管卵巢癌患者个体数据,比较新辅助化疗与初始减瘤手术的长期生存。全人群总生存无差异(HR 0.97,95%CI 0.86-1.09;p=0.586),但IV期患者新辅助化疗总生存更优(HR 0.76,95%CI 0.58-1.00;p=0.048)。
要点
- 全人群新辅助化疗与初始减瘤手术总生存无显著差异(HR 0.97,95%CI 0.86-1.09)。
- IV期患者新辅助化疗总生存更优(HR 0.76,95%CI 0.58-1.00;p=0.048)。
- 新辅助化疗是IIIC-IV期输卵管卵巢癌的有价值治疗选择,尤其高肿瘤负荷或体能状态差者。
核心结论
- 长期随访数据证实,新辅助化疗与初始减瘤手术在晚期输卵管卵巢癌中总生存相似,IV期患者新辅助化疗生存更优。
- 该汇总分析显示新辅助化疗是IIIC-IV期输卵管卵巢癌的有价值治疗选择,尤其适用于就诊时肿瘤负荷高或体能状态差的患者。
研究设计与样本
- 对EORTC 55971试验(NCT00003636)和CHORUS试验(ISRCTN74802813)个体患者数据进行符合方案汇总分析。
- 汇总分析共纳入1220例女性,EORTC试验670例,CHORUS试验550例;612例随机分配至初始减瘤手术,608例至新辅助化疗。
- EORTC试验合格者为活检证实的FIGO IIIC或IV期浸润性上皮性输卵管卵巢癌;CHORUS试验纳入标准相似,并额外纳入明显FIGO IIIA和IIIB期患者。
- 主要目标为采用反向Kaplan-Meier法显示新辅助化疗相比初始减瘤手术在总生存上的非劣效性;异质性检验基于Cochran Q统计量。
主要发现
- 中位随访7.6年(IQR 6.0-9.6);EORTC中位随访9.2年(IQR 7.3-10.4),CHORUS中位随访5.9年(IQR 4.3-7.4)。
- 中位年龄63岁(IQR 56-71),诊断时最大转移肿瘤中位大小8 cm(IQR 4.8-13.0)。
- 55例(5%)为FIGO II-IIIB期,831例(68%)为IIIC期,230例(19%)为IV期,104例(9%)分期数据缺失。
- 全人群中,新辅助化疗与初始减瘤手术的中位总生存无差异(27.6个月[IQR 14.1-51.3] vs 26.9个月[12.7-50.1];HR 0.97,95%CI 0.86-1.09;p=0.586)。
- EORTC与CHORUS患者中位总生存显著不同(30.2个月[IQR 15.7-53.7] vs 23.6个月[10.5-46.9];HR 1.20,95%CI 1.06-1.36;p=0.004),但无异质性(Cochran Q,p=0.17)。
关键数值与推荐
- 在全人群中,新辅助化疗与初始减瘤手术的中位总生存分别为27.6个月和26.9个月,HR 0.97(95%CI 0.86-1.09;p=0.586),无显著差异。
- 在IV期患者中,新辅助化疗与初始减瘤手术的中位总生存分别为24.3个月和21.2个月,HR 0.76(95%CI 0.58-1.00;p=0.048)。
- 在IV期患者中,新辅助化疗与初始减瘤手术的中位无进展生存分别为10.6个月和9.7个月,HR 0.77(95%CI 0.59-1.00;p=0.049)。
临床怎么用
- 作者认为新辅助化疗是IIIC-IV期输卵管卵巢癌的有价值治疗选择,尤其适用于就诊时肿瘤负荷高或体能状态差的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any preferable therapeutic approaches for subgroup populations. METHODS: We did a per-protocol pooled analysis of individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 55971 trial (NCT00003636) and the Medical Research Council Chemotherapy Or Upfront Surgery (CHORUS) trial (ISRCTN74802813). In the EORTC trial, eligible women had biopsy-proven International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or IV invasive epithelial tubo-ovarian carcinoma. In the CHORUS trial, inclusion criteria were similar to those of the EORTC trial, and women with apparent FIGO stage IIIA and IIIB disease were also eligible. The main aim of the pooled analysis was to show non-inferiority in overall survival with neoadjuvant chemotherapy compared with upfront debulking surgery, using the reverse Kaplan-Meier method. Tests for heterogeneity were based on Cochran's Q heterogeneity statistic. FINDINGS: Data for 1220 women were included in the pooled analysis, 670 from the EORTC trial and 550 from the CHORUS trial. 612 women were randomly allocated to receive upfront debulking surgery and 608 to receive neoadjuvant chemotherapy. Median follow-up was 7·6 years (IQR 6·0-9·6; EORTC, 9·2 years [IQR 7·3-10·4]; CHORUS, 5·9 years [IQR 4·3-7·4]). Median age was 63 years (IQR 56-71) and median size of the largest metastatic tumour at diagnosis was 8 cm (IQR 4·8-13·0). 55 (5%) women had FIGO stage II-IIIB disease, 831 (68%) had stage IIIC disease, and 230 (19%) had stage IV disease, with staging data missing for 104 (9%) women. In the entire population, no difference in median overall survival was noted between patients who underwent neoadjuvant chemotherapy and upfront debulking surgery (27·6 months [IQR 14·1-51·3] and 26·9 months [12·7-50·1], respectively; hazard ratio [HR] 0·97, 95% CI 0·86-1·09; p=0·586). Median overall survival for EORTC and CHORUS patients was significantly different at 30·2 months (IQR 15·7-53·7) and 23·6 months (10·5-46·9), respectively (HR 1·20, 95% CI 1·06-1·36; p=0·004), but was not heterogeneous (Cochran's Q, p=0·17). Women with stage IV disease had significantly better outcomes with neoadjuvant chemotherapy compared with upfront debulking surgery (median overall survival 24·3 months [IQR 14·1-47·6] and 21·2 months [10·0-36·4], respectively; HR 0·76, 95% CI 0·58-1·00; p=0·048; median progression-free survival 10·6 months [7·9-15·0] and 9·7 months [5·2-13·2], respectively; HR 0·77, 95% CI 0·59-1·00; p=0·049). INTERPRETATION: Long-term follow-up data substantiate previous results showing that neoadjuvant chemotherapy and upfront debulking surgery result in similar overall survival in advanced tubo-ovarian cancer, with better survival in women with stage IV disease with neoadjuvant chemotherapy. This pooled analysis, with long-term follow-up, shows that neoadjuvant chemotherapy is a valuable treatment option for patients with stage IIIC-IV tubo-ovarian cancer, particularly in patients with a high tumour burden at presentation or poor performance status. FUNDING: National Cancer Institute and Vlaamse Liga tegen kanker (Flemish League against Cancer).
引用
- Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018. PMID: 30413383. doi:10.1016/S1470-2045(18)30566-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。